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Background: Osteoarthritis is thought to be the most prevalent chronic and disabling joint disease in animals and
humans and its treatment is a major orthopaedic challenge because there is no ideal drug treatment to preserve
joint structure and function, as well as to ameliorate the symptomatology of the disease. The aim of the present
study was to assess, using histology, histomorphometry and micro-CT, the effects of the treatment with several drugs
of the SYSADOA group and a bisphosphonate in a model of early osteoarthritis, comparing all the results obtained.
Methods: Osteoarthritis was surgically induced by anterior cruciate ligament transection and partial meniscectomy on
one knee of 56 rabbits; treatment was started three weeks after surgery and lasted 8 weeks; at the end of this period, the
animals were sacrificed. Animals were divided into seven groups (8 animals each), one for each regimen of treatment
(glucosamine sulfate, chondroitin sulfate, hyaluronic acid, diacerein, risedronate and a combination of risedronate and
glucosamine) and one for the control (placebo-treated) group. Following sacrifice, femoral osteochondral cylinders and
synovial membrane samples were obtained for their evaluation by qualitative and quantitative histology and micro-CT.
Results: The model induced osteoarthritic changes in the knee joints and none of the treatments showed a significantly
better efficacy over the others. Regarding cartilage thickness and volume, all the treatments achieved scores halfway
between control groups, without statistical differences. Regarding the synovial membrane, diacerein and risedronate
showed the best anti-inflammatory profile, whereas glucosamine and chondroitin did not present any effect standing
the hyaluronic acid results between the others. Regarding the subchondral bone, there were no differences in thickness
or volume, but risedronate, diacerein and hyaluronic acid seemed to have considerably modified the orientation of the
trabecular lattice.
Conclusions: Out of the different drugs evaluated in the study for OA treatment, diacerein and risedronate showed, in
all the parameters measured, a better profile of effectiveness; hyaluronic acid ameliorated cartilage swelling and promoted
bone formation, but with a poor synovial effect; and finally, chondroitin and glucosamine sulfate prevented cartilage
swelling in a similar way to the others, but had no effect on cartilage surface, synovial membrane or subchondral bone.Background
Osteoarthritis (OA), the most common form of arthritis
[1], is a heterogeneous chronic disease involving all tis-
sues of the synovial joint, including cartilage, subchon-
dral bone, menisci and peri-articular soft tissues. Risk
factors include advanced age, genetic predisposition,
obesity, joint injury and abnormal joint loading [2]. It is* Correspondence: maria.permuy@usc.es
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mechanical, biochemical and genetic factors, as well as
molecular and enzymatic feedback loops, ultimately
leading to the onset and progression of the disease [3].
Osteoarthritic changes are primarily the result of a dis-
turbance in the remodelling process of joint tissues
resulting from the failure of cells to maintain a homeo-
static balance between synthesis and degradation; as the
disease advances, the catabolic process exceeds the ana-
bolic one, leading to progressive joint tissue lesions.rticle distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in
operly credited. The Creative Commons Public Domain Dedication waiver
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ent drugs that can be classified on the basis of their
mode of action. The most used options are focused on
pain relief and improvement of joint function, including
analgesics (such as acetaminophen) and non-steroidal
anti-inflammatory drugs (NSAIDs); unfortunately, their
use in chronic treatments has been limited by their dele-
terious side effects. Findings reported in the 1990’s about
the metabolic activity of cartilage and subchondral bone
led to the proposal of chondroprotective substances with
the ability to provide symptomatic relief by targeting the
underlying pathology of OA and with less secondary ef-
fects; such agents were classified as symptomatic slow-
acting drugs for OA (SYSADOAs), including cartilagin-
ous matrix precursors (glucosamine, chondroitin sulfate
and hyaluronic acid) and cytokine modulators (diacer-
ein) [4], as well as other types of drugs like bisphospho-
nates. They are expected to delay, stabilize or reverse the
pathological changes in osteoarthritic joints, limiting the
progression of the disease [5].
Glucosamine, an endogenous amino monosaccharide
synthesized by chondrocytes, is the basic precursor of the
structure of glycosaminoglycans and subsequently of aggre-
can and other proteoglycans present in cartilage, which are
part of the extracellular matrix. There are several available
glucosamine preparations (e.g. sulfate or hydrochloride)
that showed different clinical results, more favorable being
those for glucosamine sulfate than for hydrochloride [6].
Glucosamine sulfate demonstrated its efficacy and clinical
relevance in clinical trials [7] and animal models [8], help-
ing to restore the proteoglycan matrix of the cartilage, pro-
tecting damaged cartilage from metabolic impairment [9]
and showing a mild anti-inflammatory activity [10].
Chondroitin sulfate belongs to the class of natural gly-
cosaminoglycans and is an unbranched complex polysac-
charide consisting of a repeating disaccharide structure of
glucuronic acid and N-acetyl-D-galactosamine [11,12]. It
is a major component of the extracellular matrix (ECM)
where it constitutes an essential component of proteogly-
cans. Its possible usefulness for OA treatment was dem-
onstrated in animal studies [13], as well as in clinical
trials [14,15].
Hyaluronic acid is a large, viscoelastic, linear polysacchar-
ide found in the synovial fluid and cartilage. It is a macro-
molecule of several million Daltons consisting of repeating
units of D-glucuronic acid and D-acetylglucosamine [16].
The main purpose of the viscosupplementation is to make
up for the loss of viscoelasticity of the synovial fluid due to
inflammation and to protect against cartilage degradation.
Moreover, it performs biological activities in joint tissues,
such as the inhibition of the production of metalloprotein-
ases, chemokines and prostaglandins [17,18]. Its effects in
OA were also demonstrated in animals [19,20] and in
humans [21].Diacerein, an anthraquinone derivative, is an oral anti-
inflammatory, analgesic and antipyretic agent developed
specifically for the treatment of OA. Rhein, the active
metabolite, showed in vitro and in vivo the inhibition of
the IL-1β -a pro-inflammatory cytokine, which stimu-
lates the degradation process of cartilage and suppresses
cartilage matrix synthesis [22], as well as the reduction
of the collagenase production by chondrocytes, the re-
duction of the fibrinolytic activity in synovial fluid
[23,24] and the stimulation of the production of cartilage
growth factors [25], turning diacerein in an interesting
option for the OA treatment supported by the findings
in animal models [26] and in clinical trials [27].
Bisphosphonates (BPs), non-hydrolyzable analogues of
inorganic pyrophosphate, have been approved for the
treatment of pathologies with an increased bone turn-
over because they inhibit bone resorption by causing
osteoclast apoptosis. There are many clinical and experi-
mental evidences of other biological effects of BPs,
which may act on other cells such as macrophages or
chondrocytes. Bisphosphonates seem to inhibit matrix
metalloproteinases [28] and have been reported to exert
chondroprotective and analgesic effects in OA [29], even
though the exact mechanisms still remain unclear. Rise-
dronate is one of the most potent BPs and has demon-
strated beneficial effects on OA progression. It was
reported that the combination of risedronate and non-
steroidal antiinflammatory drug therapy in the early OA
stages preserve trabecular bone mass and reduce the im-
pact of osteophytic bony adaptations and bone marrow
lesions in a rat model [30]. Studies in guinea pigs suggest
smaller cartilage lesions in risedronate-treated joints ver-
sus those of animals in control groups [31]. The efficacy
of risedronate in the treatment of human OA was inves-
tigated in clinical trials with contradictory results; the
BRISK (British Study of Risedronate in Structure and
Symptoms of Knee OA) study [32] revealed clear trends
towards improvement in joint structure and symptoms;
however, the KOSTAR (Knee OA Structural Arthritis)
[33] study showed that risedronate (compared with pla-
cebo) did not alter OA progression or improve signs and
symptoms, although a reduction in biochemical markers
of cartilage degradation was observed.
Despite the numerous in vitro studies, animal models
and clinical trials supporting the beneficial effect of all
these compounds for OA, and their potential disease
modifying effect, there were some other studies in ani-
mals [34] and in humans [32] which questioned their
benefits. This calls for further research into the potential
usefulness of these therapies.
The aim of this study was to compare the effects of
several osteoarthritis treatments on a rabbit surgical
model, evaluating the magnitude of changes produced in
the knee joint after eight weeks of treatment using




Fifty-six healthy adult female New Zealand white rabbits
(Granja San Bernardo, Navarra, Spain) of 6-7 months of
age and mean weight 5 Kg were used in this study upon
approval of the protocol by the Ethical Committee of the
University of Santiago de Compostela (Reference num-
ber: AE-LU-002/09/FUN01/PAT.(06)E). Rabbits’ hous-
ing, daily monitoring and experimental procedures were
conducted in the Animal Experimentation Facility of the
University of Santiago de Compostela (Lugo, Spain) by
accredited veterinarians, trained in laboratory animal sci-
ence. All animal handling and experimentation were per-
formed in accordance with Spanish and European Union
regulations regarding care and use of research animals
and this paper has been written in line with the ARRIVE
statement [35].
The outline of the experiment, as well as the treatment
schedule is presented in Figure 1.
After the quarantine, OA was induced by anterior cru-
ciate ligament transection (ACLT) and partial medial
meniscectomy on one knee of each animal randomly
chosen. The anesthetic protocol and postoperative treat-
ment used have been widely discussed in a previous
study of our group [36]. The surgery was performed
using a lateral parapatellar approach, medial dislocationFigure 1 Experimental design. Groups of treatment.of the patella and, with the knee in maximum flexion,
anterior cruciate ligament and medial meniscus
visualization and section. After surgery, the animals were
housed in cages, allowed to perform normal activity and
monitored daily to assess changes in general health.
Three weeks after the OA induction, animals were
randomly divided for treatment into 7 groups of 8 ani-
mals each. Glucosamine sulfate, diacerein and risedro-
nate (alone and combined with glucosamine) were orally
administered diluted in normal saline (NaCl 0.9%) once
a day, chondroitin sulfate was administered diluted in
saline by intraperitoneal daily injection and hyaluronic
acid diluted in phosphate buffered saline (PBS) was ad-
ministered by intra-articular injection once a week. The
placebo group was treated with saline orally once a day.
All the dosages used in this study correspond to the hu-
man clinical doses recalculated for the rabbits’ mean
weight. Animals were treated over a period of 8 weeks
and then sacrificed for sample collection.
Necropsy and preparation of histological samples
Rabbits were sacrificed by sodium pentobarbital over-
dose (100 mg/Kg IV, Dolethal, Vétoquinol especialidades
veterinarias SA, Madrid, Spain) after sedation with keta-
mine (25 mg/Kg IM, Imalgène 1000, Merial, Toulouse,
France). All knee joints were removed and immersed in
10% buffered formalin.
The protocol used for the preparation of the histo-
logical samples as well as their processing and evaluation
Table 1 Gradation of the cartilage and synovial changes
in non-calcified samples
CARTILAGE
Severity of cartilage pathology
Normal volume, smooth Surface, intact 0
Surface undulations. Superficial zone fissures 1
Middle zone fissures and/or superficial erosions 2
Deep zone fissures and/or erosion through mid zone 3
Full thickness loss of cartilage 4
Severity of chondrocyte pathology
Normal 0
Loos of superficial cells or relative increased density with occasional
clusters
1
Small clusters (2–4 cells) predominate 2
Large clusters (up to 5 cells) predominate 3
Cell loss (necrosis/apoptosis) predominate 4
Severity of proteoglycan pathology
Normal 0
Decreased proteoglycan in the superficial zone 1
Decreased proteoglycan into the mid zone 2
Decreased proteoglycan into the deep zone 3
Full depth 4
Tidemark
Intact and distinct 0
Loss and/or duplication but distinct 1
Loss. Crossed by blood vessels 2
SYNOVIAL MEMBRANE
Lining cell characteristics
1-2 layers of cells 0
3-6 layers of cells 1






No cellular infiltration 0
Mid to moderate inflammatory infiltration. Including small lymphoid
follicles
1
Marked and diffuse inflammatory infiltration. Large lymphoid follicles. 2
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summary: After dissecting the joint, two cores of bone
and cartilage were obtained from the medial femoral con-
dyle as well as a synovial membrane section. A cylinder
was decalcified (Osteodec, Bio-Optica, Milano, Italy) and
together with the articular capsule, paraffin embedded and
stained with hematoxylin-eosin and safranin O-fast green
(in the case of the bone and cartilage cylinder). These
samples were used for evaluating OA articular changes ac-
cording to the already published guidelines [37,38]. The
assessed parameters and gradation of the changes ob-
served in the structures are summarized in Table 1.
The second cylinder was initially used to assess the 3D
architecture by a high-resolution micro-CT system
(SkyScan 1172, Bruker, Kontich, Belgium) using radiologic
parameters which have already been published [36]; due
to the different scanning conditions required to visualize
bone and cartilage, each sample was scanned twice. Next,
the samples were processed for undecalcified ground sec-
tions in accordance with the method described by Donath
[39] and stained using the Lévai-Laczkó method [40].
With micro-CT scanning, standard indices of cancel-
lous bone microstructure were determined in subchon-
dral bone [41] including bone volumetric fraction (BV/
TV; %), trabecular thickness (Tb.Th; μm) and separation
(Tb.Sp; μm), trabecular number (Tb.N; 1/mm), trabecu-
lar bone pattern factor (Tb.Pf: 1/mm), structural model
index (SMI) and degree of anisotropy (DA). In addition,
volumetric bone mineral density (vBMD; mg/cm3) was
determined by calibration against hydroxyapatite phan-
toms of known density. In cartilage, the non-calcified
cartilage volume (nCg.V; mm3) and thickness (nCg.Th;
μm) were measured three-dimensionally.
Next, the samples were used for quantitative histology
applying morphometrical parameters [42], employing
image analysis programs. The parameters evaluated
were: subchondral bone cortical thickness (SB.Th; μm);
cartilage thickness (Cg.Th; μm), measured separately for
the non-calcified (nCg.Th; μm) and the calcified cartil-
age (cCg.Th; μm) using the tidemark as reference; sur-
face cartilage undulations measured by the fibrillation
index (FI); trabecular subchondral bone area (Tb.A; %)
and separation (Tb.Sp; μm) measured in a region of
interest of 4×2 mm located immediately after the sub-
chondral cortical bone (Figure 2).Parameters evaluated in the gradation of histologic features in decalcified
paraffin embedded samples [37].Statistical approach
For the statistical evaluation, samples were divided into
eight groups: CTRL (healthy knees of the placebo-treated
group, which correspond to negative control), OA (oper-
ated knees of the placebo group, which are the positive
control), GS (operated knees of the glucosamine sulfate-
treated animals), CS (chondroitin sulfate), HA (hyaluronicacid), DC (diacerein), RS (risedronate alone) and RS +GS
(combination of risedronate and glucosamine).
Results were expressed as mean ± standard deviation.
The statistic comparison was made among all the groups
(operated knees of treated animals), the positive and the
negative controls. Normality of the data was assessed
Figure 2 Representative images of the measurements made on undecalcified sections. (A) cartilage and subcondral bone cortical thickness
(nCg.Th; cCg.Th; Cg.Th = nCg.Th + cCg.Th) SB.Th). (B). Surface undulation (FI). (C). Trabecular subchondral bone measurements in a ROI. Tb.A: % of
trabecular bone in the ROI; Tb.Sp measured on the diagonal of the ROI (Tb.Sp = (1/Tb.N)-Tb.Th).
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the equality of variances of normal variables and the statis-
tical comparison was performed using ANOVA. The post-
hoc analysis was conducted by the Holm Sidak method.
For non-normal variables, the statistical comparison was
performed using the Kruskal-Wallis H test and the post-
hoc analysis using Dunn’s test. All statistical analyses were
performed using the commercially available software Sigma
Plot 12.5 package (Systat software Inc., San Jose, CA, USA).
Differences were considered significant when p < 0.05.
Results
No changes in weight or general condition were ob-
served during the experimental protocol and the drug
administration was well tolerated by all the animals. The
only outstanding fact was that animals treated with dia-
cerein presented urine discoloration; however, no patho-
logical changes in the kidneys or other organs were
detected during necropsies. Three animals presentedTable 2 Histological Analysis
CTRL OA GS CS
mean ± SD mean ± SD mean ± SD mean
Cg pathol 0.29 ± 0.49 1 ± 0.81 1.29 ± 0.76 1.29 ±
Chondro p 0.57 ± 0.78 1.21 ± 1.15 1.86 ± 1.46 1.14 ±
PG pathol 0.33 ± 0.81 1.29 ± 1.50 1.71 ± 1.7 1.5 ± 1
Tidemark 1.12 ± 0 + 83 0.67 ± 1.03 0.17 ± 0.41 0.67 ±
Lining cells 0 ± 0 1 ± 0.63 1 ± 0.93 0.83 ±
Hyperplasia 0.13 ± 0.35 1.17 ± 0.75 1.5 ± 0.53 0.83 ±
Cell infiltrat 0 ± 0 0.67 ± 0.52 0.69 ± 0.70 0.67 ±
Histology results of decalcified core samples and synovial membrane. Cg pathol: ca
pathology; Tidemark: tidemark integrity; Cell infiltrate: cellular infiltration. Statisticalinfectious changes in the operated knee so they were ex-
cluded from the analysis (the animals belonged to the
OA, CS and HA groups).
The mean values and standard deviation of the differ-
ent treatment groups are presented in Tables 2, 3 and 4.
Regarding the parameters measured in cartilage (Table 2;
Figures 3 and 4), there were not statistical differences
among groups; although the Kruskal Wallis comparison
for the cartilage pathology was almost significant (p =
0.059) and the groups treated with diacerein (DC) and
with the combination of risedronate and glucosamine (RS
+GS) presented scores closer to the negative control
(CTRL) than the others (Figure 3). The results for the dif-
ferent groups for the severity of cartilage pathology and
chondrocyte pathology are graphically represented in a
box plot in Figure 3.
In Figure 4 the groups corresponding to the positive
control (OA), glucosamine (GS), chondroitin (CS) and
hyaluronate (HA) showed loss of the superficial structureHA DC RS RS + GS
± SD mean ± SD mean ± SD mean ± SD mean ± SD
0.76 0.9 ± 0.55 0.5 ± 0.76 1 ± 0.82 0.38 ± 0.58
1.07 1.2 ± 1.10 1.81 ± 1.19 1 ± 0.82 0.94 ± 1.01
.85 1.1 ± 1.14 1.56 ± 1.68 1.5 ± 1.76 2.38 ± 1.85
0.82 0.83 ± 0.41 0.88 ± 1.00 1 ± 0.58 0.79 ± 0.7
0.75 0 ± 0 0.29 ± 0.49 0.25 ± 0.46 0.31 ± 0.46
0.75 1.25 ± 0.46 0.86 ± 0.69 0.5 ± 0.53 0.69 ± 0.59
0.52 0.75 ± 0.89 0.29 ± 0.49 0.38 ± 0.74 0.25 ± 0.46
rtilage pathology; Chondro p: chondrocyte pathology; PG pathol: proteoglycan
significant parameters are marked in “bold text”.
Table 3 Micro-CT analysis
CTRL OA GS CS HA DC RS RS + GS
mean ± SD mean ± SD mean ± SD mean ± SD mean ± SD mean ± SD mean ± SD mean ± SD
BV/TB 48.46 ± 7.74 49.37 ± 4.38 44.74 ± 7.76 50.19 ± 50.29 52.86 ± 3.63 51.92 ± 4.99 51.71 ± 9.64 51.15 ± 2.82
Tb.Th 265.2 ± 32.62 288.75 ± 60.43 275.74 ± 82.04 286.19 ± 57.83 262.38 ± 31.06 281.18 ± 56.18 248.35 ± 18.48 255.3 ± 38.8
Tb.Sp 467.24 ± 32.6 423.12 ± 66.2 478.00 ± 64.74 431.02 ± 55.25 353.7 ± 37.75 433.27 ± 54.03 367.53 ± 61.9 385.09 ± 61.9
Tb.N 1.83 ± 0.20 1.76 ± 0.29 1.68 ± 0.28 1.77 ± 0.16 2.34 ± 0.23 1.89 ± 0.30 2.07 ± 0.3 2.03 ± 0.25
Tb.Pf -3.27 ± 1.49 -3.24 ± 0.51 -3.15 ± 1.81 -3.76 ± 1.95 -4.17 ± 1.43 -4.01 ± 1.15 -4.09 ± 2.92 -4.31 ± 0.95
SMI -0.66 ± 0.47 -0.72 ± 0.39 -0.51 ± 0.44 -0.88 ± 0.85 -0.85 ± 0.53 -0.96 ± 0.60 -0.87 ± 1.09 -0.8 ± 0.35
DA 0.71 ± 0.06 0.69 ± 0.06 0.71 ± 0.05 0.61 ± 0.06 0.51 ± 0.04 0.57 ± 0.06 0.53 ± 0.10 0.52 ± 0.08
nCg.Th 309.06 ± 63.0 494.8 ± 169.6 369.71 ± 113.74 388.04 ± 114.15 413.43 ± 55.2 359.75 ± 48.62 391.41 ± 68.7 359.77 ± 131.4
nCg.V 3.37 ± 0.78 5.69 ± 2.73 3.37 ± 1.49 3.68 ± 1.24 4.27 ± 1.56 3.71 ± 0.50 3.47 ± 1.11 3.29 ± 1.43
vBMD 505.9 ± 98.53 512.78 ± 52.52 471.32 ± 108.96 531.31 ± 68.58 562.51 ± 34.00 548.69 ± 58.95 549.24 ± 109.9 568.14 ± 42.44
Micro-CT results. BV/TV: bone volume/tissue volume; Tb.Th: trabecular thickness; TB.Sp: trabecular separation; Tb.N: trabecular number; Tb.Pf: trabecular pattern
factor; SMI: structural model index; DA: degree of anisotropy; nCg.Th: non-calcified cartilage thickness; nCg.V: non-calcified cartilage volume; vBMD: volumetric bone
mineral density. Statistical significant parameters are marked in “bold text”.
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the superficial layers of the cartilage. The chondrocyte dis-
organisation, with cells not arranged in rows and the evi-
dent formation of clusters, could be observed with greater
intensity in the images corresponding to the OA, GS and
CS groups, whereas in DC, RS and RS +GS cells are better
organized (similar to those in the negative control CTRL).
Regarding the synovial membrane (Table 2, Figures 3
and 5), the only measure that did not show any differ-
ences in the analysis of variance was cell infiltration; the
others showed statistical differences, with p = 0.003 for
the lining cells and p < 0.001 for hyperplasia (results
plotted in Figure 3). When a multiple comparison
method was used to isolate the groups, it was impossible
to identify the differences in lining cells whereas in
hyperplasia the differences were shown between CTRL-
GS, CTRL-HA and CTRL-OA and also between GS and
RS (Figure 3).
It is important to mention that the behaviur of the HA
group in lining cell characteristics was the same as the
one shown by the negative control (CTRL) with p = 1.Table 4 Histomorphometrical analysis
CTRL OA GS CS
mean ± SD mean ± SD mean ± SD mean ± SD
Tb.A 46.4 ± 5.4 47.9 ± 7.01 39.8 ± 8.8 44.5 ± 5.8
Tb.Sp 514.9 ± 235.2 437.8 ± 211.9 593.9 ± 214.4 503.3 ± 141
SB.Th 306.6 ± 76.5 251.6 ± 67.4 273.1 ± 109.96 288.1 ± 85.
FI 1.1 ± 0.07 1.2 ± 0.14 1.3 ± 0.3 1.35 ± 0.6
Cg.Th 493.7 ± 80.7 620.1 ± 114.8 522.07 ± 120.1 506.4 ± 128
nCg.Th 338.6 ± 65.03 465.2 ± 88.9 364.6 ± 98.6 375.9 ± 113
cCg.Th 155.09 ± 24.9 167.75 ± 43.01 160.7 ± 25.8 132.6 ± 27.
Histomorphometry scores of undecalcified samples. TB.A: trabecular area; Tb.Sp: trab
Cg.Th: total cartilage thickness; nCg.Th: non-calcified cartilage thickness; cCg.Th: calcIn the synovial membrane of the negative control
group (CTRL) (Figure 5) the lining surface was thin,
with one or two layers of cells, the surface was smooth,
with no presence of short villi or finger-like hyperplasia,
or of inflammatory infiltrations. The OA group (positive
control) was in the opposite situation, with a thick lining
surface, profuse hyperplasia, presence of diffuse inflam-
matory infiltration and a deposition of fibrous tissue
below the intima tissue. The chondroitin sulfate (CS)
and glucosamine sulfate (GS) showed an image similar
to those of the OA group (with hyperplasia and more
than two layers of superficial cells) but with less fibrous
tissue in the subintima. Finally, in the other treatment
groups (DC, HA, RS and RS + GS), the number of super-
ficial cell layers tends to approach the one of controls, as
well as hyperplasia, exhibiting less fibrous subintima tis-
sue than the OA group but it is more marked than in
the control group.
Regarding the parameters measured by micro-CT
(Table 3, Figure 6), the statistical differences were found
in the trabecular number (Tb.N; p = 0.018), trabecularHA DC RS RS + GS
mean ± SD mean ± SD mean ± SD mean ± SD
43.2 ± 6.1 45.5 ± 6.8 41.7 ± 8.1 38.9 ± 5.55
.7 465.6 ± 139.5 590.1 ± 272.7 528.2 ± 272.7 731.26 ± 189.3
01 237.6 ± 50.5 268.2 ± 47.01 274.6 ± 96.7 229.7 ± 64.6
1.14 ± 0.1 1.1 ± 0.05 1.06 ± 0.07 1.09 ± 0.13
.8 536.8 ± 98.9 571.1 ± 96.7 499.05 ± 56.4 555.7 ± 120.1
.3 411.2 ± 90.5 409.8 ± 82.6 320.3 ± 58.2 408.6 ± 88.7
08 129.06 ± 18.4 161.3 ± 42.09 140.1 ± 35.8 156.01 ± 26.35
ecular separation; SB.Th: subchondral bone thickness; FI: fibrillation index;
ified cartilage thickness.
Figure 3 Box plot comparing the scores obtained by the different experimental groups for qualitative microscopic grading of cartilage and
synovial alterations (decalcified samples). In hyperplasia of the synovial membrane the differences were shown between CTRL-GS, CTRL-HA and
CTRL-OA and also between GS and RS. The rest of the parameters did not show differences among groups.
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ropy (DA; p < 0.001). When the groups were compared,
Tb.N showed no significant differences while Tb.Sp
showed them between GS and HA. With respect to the
DA differences, they were found between CTRL-HA (p <
0.001), CTRL-DC (p = 0.003), CTRL-RS (p < 0.001),
CTRL-RS +GS (p < 0.001), GS-HA (p < 0.001), GS-DC
(p = 0.006), GS-RS (p < 0.001) and GS-RS +GS (p < 0.001);
also between the OA-HA (p < 0.001), OA-DC (p = 0.018),
OA-RS (p < 0.001) and OA-RS +GS (p < 0.001) groups.
The results of these parameters are graphically repre-
sented in a box plot diagram in Figure 6.
The nCg.Th and nCg.V scores of all the treatment
groups were halfway between the negative and the positive
controls, but without statistical differences (Figure 6).Regarding histomorphometry (Table 4; Figures 6 and 7),
there was no statistical significance among groups in any
of the parameters measured, although the superficial fib-
rillation index (FI) showed a trend to approximate to the
control group values. When the FI scores were observed
in further detail, the DC, RS and RS +GS groups pre-
sented mean scores equal or even below those of the
CTRL group while HA obtained scores halfway between
CTRL and OA, whereas the other treatment groups (GS,
CS) even higher values than OA (Figure 6). In the same
way as in micro-CT, within the group of treated animals,
the scores of the three measurements of cartilage thick-
ness (total, non-calcified and calcified) were halfway be-
tween CTRL and OA, but they did not present any
significant differences compared to any of them.
Figure 4 Decalcified cartilage samples. Representative histology images of the treatment groups in decalcified samples stained with Safranin-O.
Magnification 10X. CTRL: healthy knees of the placebo-treated group; OA: osteoarthritic knees of the placebo group; GS: glucosamine sulfate;
CS: chondroitin sulfate; HA: hyaluronic acid; DC: diacerein; RS: risedronate; RS + GS: risedronate + glucosamine.
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stained with Levai-Lazckó (Figure 7), despite small dif-
ferences in the statistical analysis, several differences be-
tween groups were observed. Total cartilage (Cg.Th) of
the OA group was thicker than the others, all the treat-
ment groups reaching intermediate values between CTRL
and OA. Another important finding that may be visualized
in the images is that the OA group had more superficial
fibrillation than CTRL (negative control). The images of
the diacerein (DC), risedronate (RS) and risedronate plus
glucosamine (RS +GS), as well as hyaluronic acid (HA)
groups, showed less superficial irregularities similar to the
negative control (CTRL), whereas glucosamine (GS) and
chondroitin (CS) groups had more fibrillation. The distri-
bution of chondrocytes in the cartilage layer, although the
cell distribution and cluster formation were not evaluated
in these calcified samples, was different too, showing more
disorganization in the OA group than in the others. Fi-
nally, in the image of the OA group, the partial loss of theFigure 5 Synovial membrane. Representative histology images of the syno
knees of the placebo-treated group; OA: osteoarthritic knees of the placebo
acid; DC: diacerein; RS: risedronate; RS + GS: risedronate + glucosamine.calcified cartilage (cCg.Th) could be observed, as well as
in the glucosamine and chondroitin sulfate images, unlike
in the others.
Discussion
Animal models for OA, including rabbits, provide an
important opportunity to solve the current controversy
as to whether different drugs have a structure which
leads to a detectable effect or not. Surgically induced
models, resulting in joint instability, produce a gradual
progression of degeneration which mimics the patho-
genesis of the human traumatic OA [43,44]. Previously
published data showed that most rabbits with ACLT
develop cartilage degeneration and subchondral bone
alterations [45] as soon as 8 weeks post-surgery. In the
present study the OA was enough to produce detect-
able changes in several joint tissues, although it was
still in an initial stage (changes are more evident in the
placebo OA group). The articular cartilage is in a statevial membrane. Stained with H-E. Magnification 20X. CTRL: healthy
group; GS: glucosamine sulfate; CS: chondroitin sulfate; HA: hyaluronic
Figure 6 Box plot comparing the scores obtained by the different experimental groups for micro-CT and quantitative histomorphometry. In Tb.Sp
measured by micro CT the groups that showed significance were GS vs. HA. In the parameter DA (degree of anisotropy) there were statistical
differences between: CTRL-HA (p < 0.001), CTRL-DC (p = 0.003), CTRL-RS (p < 0.001), CTRL-RS + GS (p < 0.001), GS-HA (p < 0.001), GS-DC (p = 0.006),
GS-RS (p < 0.001) and GS-RS + GS (p < 0.001); also between the OA-HA (p < 0.001), OA-DC (p = 0.018), OA-RS (p < 0.001) and OA-RS + GS (p < 0.001).
In the rest of the parameters the differences were not significant.
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ease, previous to its erosion and destruction [46] and
the synovial membrane revealed moderate to severe in-
flammatory changes; in contrast, probably because the
study was conducted in an early model, the subchon-
dral bone did not present the sclerosis typical to thisFigure 7 Calcified samples. Representative histology images of the histomorp
10X. CTRL: healthy knees of the placebo-treated group; OA: osteoarthritic knee
HA: hyaluronic acid; DC: diacerein; RS: risedronate; RS + GS: risedronate + glucodisease. Thus, the results of the present study indicate
that ACLT and partial medial meniscectomy in rabbits
produce detectable OA changes, supporting the out-
comes of previous studies [45] and therefore the effects
of these compounds should be subjected to further
studies.hometry samples. Non-decalcified. Levai-Laczkó staining. Magnification
s of the placebo group; GS: glucosamine sulfate; CS: chondroitin sulfate;
samine.
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[47] or modified Mankin scoring systems in decalcified
samples are considered as the gold standard [42]. How-
ever, because of its subjectivity and the possibility of
inter- and/or intra-observer variability, the histomorpho-
metry of calcified samples, using computer analysis sys-
tems, was introduced with a greater degree of objectivity
and reproducibility [42].
Micro-CT has become in recent years the gold standard
for three-dimensional analysis of bone microstructure, but
when dealing with soft tissues, as cartilage, the technique
usually has to be modified using complex staining
methods with radiopaque contrast agents, due to its low
X-ray transmission [48,49]; in the present study, the scan-
ning conditions were adjusted to achieve a correct
visualization of the cartilage, sufficient to provide any
quantification of its morphology without staining (the
scanning conditions used have been previously pub-
lished [34]), thus the same biopsy could be used for both
micro-CT and histomorphometry. The fact that PC-
based histomorphometry and micro-CT techniques proved
to be reproducible and objective methods is very significant.
In this study, for a complete characterization of cartil-
age, subchondral bone and synovial membrane in OA
and the evaluation of the effects of different chondro-
protective drugs, quantitative (histomorphometry) and
qualitative microscopic evaluations were used, as well as
micro-CT scanning. The results obtained by micro-CT
and histomorphometry were comparable and better than
those obtained for the decalcified samples, probably due
to the combination of a better structure conservation of
the calcified tissues (chiefly bone and calcified cartilage)
that could be altered by decalcification [42] and the lack
of possible substantial intra- and inter-observer variabil-
ity of qualitative scoring methods.
Analyses of several randomized clinical trials and
animal studies support the contention that the drugs
studied are symptom-modifying agents, and may be
structure-modifying agents, whereas others have de-
tected no effect. These compounds are currently rec-
ommended by the EULAR (European League Against
Rheumatism) [50,51] and the ESCEO (European Soci-
ety for Clinical and Economic aspects of Osteoporosis
and Osteoarthritis) [52] whereas, in contrast, in 2014
they were recommended as “uncertain” by the OARSI
(Osteoarthritis Research Society International). The
OARSI experts did not consider the term “uncertain”
as a negative recommendation; rather it requires a role
for physician-patient interaction because of their favor-
able risk-benefit ratio and its moderate to high effect
size. In the case of risedronate, the last update of the
OARSI consider it as not recommendable because of
the lack of well-conducted studies to guarantee its
efficacy [53].In our study none of the treatments administered pre-
sented a remarkable better efficacy over the others; how-
ever, all of them, to a greater or lesser extent, demonstrated
a tendency towards the amelioration of the pathological
changes evaluated in cartilage, bone or synovial mem-
brane. When the thickness and volume of the cartilage
were measured (both micro-CT and histomorphometry)
all the treatment groups achieve scores halfway between
negative and positive controls, but without statistical dif-
ferences. As mentioned before, several studies in animal
models of early OA identified an initial phase of cartilage
hypertrophy prior to its degeneration and loss [46] and, al-
though the explanation of this phenomenon was not clari-
fied yet, it could be an expression of the inflammation and
an attempt of tissue reparation. In the present study the
results confirm that with the administration of either of
the studied compounds this related phenomenon was less
pronounced, indicating its possible anti-inflammatory ef-
fect on cartilage.
The anti-inflammatory effect observed on the synovial
membrane was different for the drugs used: diacerein
and risedronate (alone or with glucosamine) presented a
higher degree of effectivity as anti-inflammatories
against synovitis, whereas glucosamine and chondroitin
sulfate did not show any effect in ameliorating synovitis,
and the hyaluronic acid was in-between the others;
these results shown by glucosamine and chondroitin
were different to previously published studies, in which
improvement in the synovial inflammation was ob-
served [54,55].
Regarding the superficial fibrillation index (FI) –an
important parameter that provides a significant discrim-
ination between ill and healthy animals [56]- the diacer-
ein and the risedronate treatment (alone or combined)
suggested a possible effect in slowing the disease cor-
roborating the results previously observed by other au-
thors [57,58]; whereas, the treatment with glucosamine
alone or with chondroitin sulfate did not ameliorate the
cartilage superficial fibrillation, which is in accordance
with the results obtained in previous studies, where
authors did not find prevention of the fibrillation or
erosions of the articular cartilage surface with these
drugs [8,59].
Finally, in this study the subchondral bone thickness
and volume were not altered in any group; however, dia-
cerein, hyaluronic acid and risedronate (alone and com-
bined) seemed to considerably modify the orientation of
the subchondral trabecular lattice (resented by a reduc-
tion in trabecular separation and an increase in trabecu-
lar number, a trend to bone formation as well as an
increase in bone mineral density). Early in the pathogen-
esis of OA, prior to the development of sclerosis, there
is a period of periarticular osteopenia [60] and a signifi-
cant reduction in bone mineral density was reported in
Permuy et al. BMC Musculoskeletal Disorders  (2015) 16:120 Page 11 of 12patients with mild OA when it was compared to healthy
ones [61]. These effects on bone were expected in the
animals treated with risedronate, a potent aminobispho-
phonate, which showed its effectiveness in conserving
the periarticular bone [62]. In the same way, high molecu-
lar weight hyaluronic acid was shown to promote human
osteoblast bone matrix protein expression in vitro [63]
and bone formation in vivo [64] as well as to reduce bone
resorption, but no study on this effect of diacerein on
bones, to the best of the authors’ knowledge, has been
published yet.
Conclusions
The aim of the study was to compare the effects of the
treatment with different OA drugs on an early model in
rabbits. Out of the drugs used, diacerein and risedronate
(alone or combined with glucosamine) were the com-
pounds with a better profile of effectiveness in ameliorat-
ing these early changes, showing a better anti-inflamatory
effect (in cartilage and synovial membrane), improving the
cartilage surface alterations and increasing bone density.
On the other hand, hyaluronic acid ameliorated cartilage
swelling and promoted bone formation, but had less effect
on the synovial membrane and its effects in preventing
cartilage superficial erosion were also milder than those of
risedronate and diacerein. Finally, in the present study,
glucosamine and chondroitin sulfate only prevented
cartilage swelling, in a similar way as the others, but had
no effect on the cartilage surface, synovial membrane or
subchondral bone.
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